Personally I think that management is just very inexperienced with "Investor Relations". Inserting the R/S clause and then retracting it is proof of point on that.
We also KNOW that mgmt will need to dilute to pay the bills and conduct the trials. So no one should be surprised when we see the O/S and float climb over the next 6-12 months.
However, due to the current LOW O/S and float, I'm keeping a longer term perspective on this (out to spring/summer 2022) while I wait for positive events to unfold.
Mgmt also needs to do a better job at issuing PRs to keep the investor community up-to-date on current events with the physical construction efforts and their clinical trial progress. That would help support a floor on the PPS.
News 
Market Data 
Discover 
AI
